Principal causal effect identification and surrogate end point evaluation by multiple trials

被引:16
|
作者
Jiang, Zhichao [1 ]
Ding, Peng [2 ]
Geng, Zhi [1 ]
机构
[1] Peking Univ, Beijing, Peoples R China
[2] Univ Calif Berkeley, Berkeley, CA 94720 USA
基金
中国国家自然科学基金;
关键词
Causal inference; Causal necessity; Causal sufficiency; Clinical trial; Criterion for surrogate end points; POTENTIAL OUTCOMES; AUGMENTED DESIGNS; VACCINE TRIALS; STRATIFICATION; INFERENCE; NONCOMPLIANCE; CRITERIA; MODELS; DEATH; DISTRIBUTIONS;
D O I
10.1111/rssb.12135
中图分类号
O21 [概率论与数理统计]; C8 [统计学];
学科分类号
020208 ; 070103 ; 0714 ;
摘要
Principal stratification is a causal framework to analyse randomized experiments with a post-treatment variable between the treatment and end point variables. Because the principal strata defined by the potential outcomes of the post-treatment variable are not observable, we generally cannot identify the causal effects within principal strata. Motivated by a real data set of phase III adjuvant colon cancer clinical trials, we propose approaches to identifying and estimating the principal causal effects via multiple trials. For the identifiability, we remove the commonly used exclusion restriction assumption by stipulating that the principal causal effects are homogeneous across these trials. To remove another commonly used monotonicity assumption, we give a necessary condition for the local identifiability, which requires at least three trials. Applying our approaches to the data from adjuvant colon cancer clinical trials, we find that the commonly used monotonicity assumption is untenable, and disease-free survival with 3-year follow-up is a valid surrogate end point for overall survival with 5-year follow-up, which satisfies both causal necessity and causal sufficiency. We also propose a sensitivity analysis approach based on Bayesian hierarchical models to investigate the effect of the deviation from the homogeneity assumption.
引用
收藏
页码:829 / 848
页数:20
相关论文
共 50 条
  • [31] Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials
    Collette, Laurence
    EUROPEAN UROLOGY, 2008, 53 (01) : 6 - 9
  • [32] Glomerular filtration rate as a putative 'surrogate end-point' for renal transplant clinical trials in children
    Filler, G
    Browne, R
    Seikaly, MG
    PEDIATRIC TRANSPLANTATION, 2003, 7 (01) : 18 - 24
  • [33] Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials
    Gabler, Nicole B.
    French, Benjamin
    Strom, Brian L.
    Palevsky, Harold I.
    Taichman, Darren B.
    Kawut, Steven M.
    Halpern, Scott D.
    CIRCULATION, 2012, 126 (03) : 349 - +
  • [34] A unified procedure for meta-analytic evaluation of surrogate end points in randomized clinical trials
    Dai, James Y.
    Hughes, James P.
    BIOSTATISTICS, 2012, 13 (04) : 609 - 624
  • [35] Assessment of Surrogate End Point Trends in Clinical Trials to Approve Oncology Drugs From 2001 to 2020 in Japan
    Maeda, Hideki
    Shingai, Riko
    Takeda, Kentaro
    Hara, Asuka
    Murai, Yuna
    Ofuchi, Momoka
    JAMA NETWORK OPEN, 2023, 6 (04) : E238875
  • [36] Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials - Discussion
    MacMahon, S
    Devereux, R
    Zanchetti, A
    AgabitiRosei, E
    Hansson, L
    Swales, JD
    JOURNAL OF HYPERTENSION, 1996, 14 : S101 - S102
  • [37] GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials
    Inker, Lesley A.
    Heerspink, Hiddo J. L.
    Tighiouart, Hocine
    Levey, Andrew S.
    Coresh, Josef
    Gansevoort, Ron T.
    Simon, Andrew L.
    Ying, Jian
    Beck, Gerald J.
    Wanner, Christoph
    Floege, Juergen
    Li, Philip Kam-Tao
    Perkovic, Vlado
    Vonesh, Edward F.
    Greene, Tom
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2019, 30 (09): : 1735 - 1745
  • [38] End points for adjuvant therapy trials: Has the time come to accept disease-free survival as a surrogate end point for overall survival?
    Gill, Sharlene
    Sargent, Daniel
    ONCOLOGIST, 2006, 11 (06): : 624 - 629
  • [39] Shift From Surrogate End Point to Outcome Trials: Implications for Cardiovascular Safety Assessment in Development Programs for Antidiabetic Drugs
    Marcinak, J. F.
    Viswanathan, P.
    Arora, V.
    Roebel, L. E.
    Strack, T. R.
    Leifke, E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (03) : 514 - 520
  • [40] The effect of statins on average survival in randomised trials, an analysis of end point postponement
    Kristensen, Malene Lopez
    Christensen, Palle Mark
    Hallas, Jesper
    BMJ OPEN, 2015, 5 (09):